Clinical trial · Interventional
Bone Reconstruction With Autologous Bone Marrow Mesenchymal Stem Cells in Vitro to Repair Long Tubular Bone Defects
Clinical Transformation of Bone Reconstruction With Autologous Bone Marrow Mesenchymal Stem Cells in Vitro to Repair Long Tubular Bone Defects of Limbs
NCT07066228CI-TRIAL-00099970recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Commercial decalcified bone scaffolds were combined with autologous bone marrow mesenchymal stem cells to form tissue engineered bone in vitro to explore the effect of this tissue engineered bone in the clinical repair of long tubular bone defects in limbs.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Cysts | — | UNRESOLVED | — |
| Bone Defect | — | UNRESOLVED | — |
| Bone Nonunion | — | UNRESOLVED | — |
| Defective Composite Restorations | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| tissue-engineered bone | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Tissue engineered bone on bone defect
- interventionNames
- Device: tissue-engineered bone
Primary outcomes (3)
- measure
- The scores of bone healing
- timeFrame
- About 360 days after surgical treatment of bone defect
- description
- The scores of bone healing are divided into three kinds: nonhealing: 0;delayed healing: 1; normal healing.
- measure
- The adverse event incidence using tissue-engineered bone
- timeFrame
- About 360 days after surgical treatment of bone defect
- description
- The adverse event incidence of tissue-engineered bone
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 55 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age: 18-55 years old, gender unrestricted; 2. Defective nonunion with bone loss exceeding 30% of the bone cross-section and a length of 2-3 cm; 3. Solitary bone cysts involving more than 50% of the bone cross-section. Exclusion Criteria: 1. Combined with local tumors, tuberculosis, infections or other bone-healing affecting lesions; 2. Systemic diseases affecting bone healing such as osteofibrous dysplasia, osteogenesis imperfecta, bone dystrophic diseases, and metabolic bone disorders; 3. Moderate-to-severe osteoporosis (BMD: T-score \< -2.5); 4. Severe systemic conditions including systemic malnutrition, systemic infectious diseases, severe cardiopulmonary diseases, coagulation disorders, and major organ failure; 5. Complicated with severe brain trauma; 6. Heavy smoking, drug abuse, alcoholism, or other harmful addictions; 7. Psychiatric disorders or patients with menopausal symptoms; 8. Concurrent participation in other studies or recent completion (within 4 weeks) of other clinical trials; 9. Pregnancy, lactation, or planned pregnancy within one year after initial enrollment; 10. Psychological conditions impairing treatment compliance; 11. Congenital malformations of vital organs or other systems; 12. Nonunion caused by malignant tumor resection; 13. Refusal to accept tissue-engineered bone repair protocol.
References
Publications (0)
Data not yet available
No reference posted for this study.